| Market Capitalization (Millions $) |
68,604 |
| Shares
Outstanding (Millions) |
207 |
| Employees |
7,550 |
| Revenues (TTM) (Millions $) |
12,872 |
| Net Income (TTM) (Millions $) |
3,146 |
| Cash Flow (TTM) (Millions $) |
97 |
| Capital Exp. (TTM) (Millions $) |
1,862 |
Biogen Inc.
Biogen Idec creates new standards of care in oncology and immunology. As a global
leader in the development, manufacturing, and commercialization of novel therapies,
we transform scientific discoveries into advances in human healthcare. We currently
have four commercial products: AVONEX® (Interferon beta-1a) for the treatment
of relapsing multiple sclerosis, also known as MS, RITUXAN® (rituximab) and ZEVALIN®
(ibritumomab tiuxetan), both of which treat certain B-cell non-Hodgkin’s lymphomas,
also referred to as B-cell NHLs, and AMEVIVE® (alefacept) for the treatment of
adult patients with moderate-to-severe chronic plaque psoriasis who are candidates
for systemic therapy or phototherapy.
| BIIB is expected to report next financial results on October 22, 2018. |
|
|
29.25 %